Form 4 Filing for Fennec Pharmaceuticals Inc.

Jeffrey S. Hackman, Chief Executive Officer and Director of Fennec Pharmaceuticals Inc., acquired 1159 common shares on July 31, 2026. The shares were acquired at a price of $0.0 per share. This transaction resulted in a post-transaction share count of 65,143. The shares acquired were released from restriction, as they were awarded on March 28, 2025. This filing is a Form 4, indicating a change in beneficial ownership.